The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib (Q40328353)
Jump to navigation
Jump to search
scientific article published on May 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib |
scientific article published on May 2006 |
Statements
1 reference
The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib (English)
1 reference
1 reference
1 reference
Adele Carotenuto
1 reference
Monica R Maiello
1 reference
Manuela Campiglio
1 reference
Mario Mancino
1 reference
Sylvie Menard
1 reference
Maria Napolitano
1 reference
Giuseppe Viglietto
1 reference
1 May 2006
1 reference
1 reference
207
1 reference
2
1 reference
420-427
1 reference
Identifiers
1 reference
1 reference